Singapore, April 10 -- Genetron Holdings Limited (Genetron Health), a China-based precision oncology company that covers full-cycle cancer care, announces that its independently developed Detection Kit for Novel Coronavirus (SARS-CoV-2) RNA (PCR-Fluorescence Probing) has been issued CE marking and had its application accepted by FDA-EUA.

Based on the test kit, three of Genetron Health's clinical laboratories have passed the COVID-19 External Quality Assessment (EQA) by China's National Center for Clinical Laboratories (NCCL).

In addition to CE marking and FDA-EUA application acceptance, Genetron Health's nucleic acid detection kit has also performed excellently in a verification project held by the Beijing Center for Disease Prevention ...